000292121 001__ 292121
000292121 005__ 20251006143254.0
000292121 0247_ $$2doi$$a10.1200/JCO.24.00709
000292121 0247_ $$2pmid$$apmid:39110925
000292121 0247_ $$2ISSN$$a0732-183X
000292121 0247_ $$2ISSN$$a1527-7755
000292121 0247_ $$2altmetric$$aaltmetric:166072584
000292121 037__ $$aDKFZ-2024-01620
000292121 041__ $$aEnglish
000292121 082__ $$a610
000292121 1001_ $$00000-0001-7733-383X$$aHansford, Jordan R$$b0
000292121 245__ $$aComments and Controversies in Oncology: The Tribulations of Trials Developing ONC201.
000292121 260__ $$aAlexandria, Va.$$bAmerican Society of Clinical Oncology$$c2024
000292121 3367_ $$2DRIVER$$aarticle
000292121 3367_ $$2DataCite$$aOutput Types/Journal article
000292121 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1733492953_12799
000292121 3367_ $$2BibTeX$$aARTICLE
000292121 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292121 3367_ $$00$$2EndNote$$aJournal Article
000292121 500__ $$a2024 Dec 10;42(35):4126-4129
000292121 520__ $$aOur international team highlights issues with efficacy reports in several studies on DMG with the new drug ONC201.
000292121 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000292121 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292121 7001_ $$aBouche, Gauthier$$b1
000292121 7001_ $$aRamaswamy, Vijay$$b2
000292121 7001_ $$aJabado, Nada$$b3
000292121 7001_ $$aFonseca, Adriana$$b4
000292121 7001_ $$aMoloney, Sam$$b5
000292121 7001_ $$aGottardo, Nicholas G$$b6
000292121 7001_ $$aRobinson, Giles W$$b7
000292121 7001_ $$aGajjar, Amar$$b8
000292121 7001_ $$aTinkle, Christopher L$$b9
000292121 7001_ $$aFisher, Paul G$$b10
000292121 7001_ $$aForeman, Nicholas$$b11
000292121 7001_ $$aAshley, David M$$b12
000292121 7001_ $$aZiegler, David S$$b13
000292121 7001_ $$aEisenstat, David D$$b14
000292121 7001_ $$aMassimino, Maura$$b15
000292121 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b16$$udkfz
000292121 7001_ $$0P:(DE-He78)500a1860cab2d28ce2718dc7920c7587$$aBartels, Ute$$b17$$udkfz
000292121 7001_ $$aRutkowski, Stefan$$b18
000292121 7001_ $$aHargrave, Darren$$b19
000292121 7001_ $$aFouladi, Maryam$$b20
000292121 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b21$$udkfz
000292121 7001_ $$aBouffet, Eric$$b22
000292121 773__ $$0PERI:(DE-600)2005181-5$$a10.1200/JCO.24.00709$$gp. JCO.24.00709$$n35$$p4126-4129$$tJournal of clinical oncology$$v42$$x0732-183X$$y2024
000292121 8564_ $$uhttps://inrepo02.dkfz.de/record/292121/files/hansford-et-al-2024-comments-and-controversies-in-oncology-the-tribulations-of-trials-developing-onc201.pdf
000292121 8564_ $$uhttps://inrepo02.dkfz.de/record/292121/files/hansford-et-al-2024-comments-and-controversies-in-oncology-the-tribulations-of-trials-developing-onc201.pdf?subformat=pdfa$$xpdfa
000292121 909CO $$ooai:inrepo02.dkfz.de:292121$$pVDB
000292121 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000292121 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)500a1860cab2d28ce2718dc7920c7587$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000292121 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000292121 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000292121 9141_ $$y2024
000292121 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-22$$wger
000292121 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000292121 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-22
000292121 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000292121 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-22
000292121 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000292121 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-22
000292121 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-22
000292121 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
000292121 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN ONCOL : 2022$$d2023-10-22
000292121 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000292121 915__ $$0StatID:(DE-HGF)9940$$2StatID$$aIF >= 40$$bJ CLIN ONCOL : 2022$$d2023-10-22
000292121 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000292121 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000292121 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x2
000292121 980__ $$ajournal
000292121 980__ $$aVDB
000292121 980__ $$aI:(DE-He78)B062-20160331
000292121 980__ $$aI:(DE-He78)HD01-20160331
000292121 980__ $$aI:(DE-He78)B310-20160331
000292121 980__ $$aUNRESTRICTED